-+ 0.00%
-+ 0.00%
-+ 0.00%

Wolfe Research Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $45

Benzinga·07/07/2026 10:40:36
Listen to the news
Wolfe Research analyst Rudy Li initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Outperform rating and announces Price Target of $45.